Skip to main content
TipRanks
Go Ultimate75% OFF

Top Page

PJP

Invesco Dynamic Pharmaceuticals ETF (PJP)

Rating:70Neutral
Price Target:$137.00â–²(4.55% Upside)

PJP, the Invesco Dynamic Pharmaceuticals ETF, has a solid overall rating that reflects a portfolio led by strong, established drug makers with generally healthy financials and growth prospects. Key holdings like Merck and Johnson & Johnson support the fund’s quality through robust performance, positive earnings outlooks, and strategic pipelines, while weaker names such as Perrigo and Viatris, which face profitability and valuation challenges, slightly weigh on the rating. The main risk for investors is the fund’s concentration in the pharmaceutical sector, meaning it is heavily exposed to industry-specific issues like drug pricing pressures, patent risks, and regulatory changes.

Positive Factors
Strong Year-to-Date PerformanceThe ETF has delivered strong gains so far this year, showing solid momentum in its strategy.
Leading Pharmaceutical HoldingsMany of the top holdings, including several major drug makers, have shown strong performance, helping support the fund’s returns.
Focused Exposure to Health CareThe fund’s near-total focus on U.S. health care and pharmaceuticals gives investors targeted access to a defensive, essential sector.
Negative Factors
High Sector ConcentrationAlmost all assets are in the health care sector, so the ETF is heavily exposed to industry-specific risks like drug pricing and regulation.
Limited Geographic DiversificationWith nearly all holdings in U.S. companies, the fund offers little protection if the U.S. market or domestic health care policies face pressure.
Above-Average Expense RatioThe ETF’s fee is relatively high for a passive sector fund, which can slightly reduce the net returns investors receive over time.

PJP vs. SPDR S&P 500 ETF (SPY)

-5%0%5%10%15%20%25%30%SPY+14.55%PJP+27.13%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AUM
609.17M
Region
North America
Expense Ratio
0.58%
Beta
0.53
Issuer
Invesco
Inception Date
Jun 23, 2005
Dividend Yield
0.86%
Asset Class
Equity
Index Tracked
Dynamic Pharmaceutical Intellidex Index (AMEX)

PJP Summary

PJP is the Invesco Dynamic Pharmaceuticals ETF, which follows the Dynamic Pharmaceutical Intellidex Index. It focuses on U.S. drugmakers and health care companies involved in developing and selling medicines. The fund holds well-known names like Pfizer and Johnson & Johnson, along with other major pharmaceutical firms. Someone might invest in PJP to tap into the long-term growth potential of new treatments and the steady demand for health care, while spreading their money across many companies instead of picking just one. A key risk is that it is heavily concentrated in pharmaceutical stocks, so its value can rise or fall sharply with changes in the drug industry and health care regulations.

How much will it cost me?

PJP has an annual expense ratio of 0.58%, which means you’ll pay about $5.80 per year for every $1,000 invested. This cost is higher than the average ETF because it uses a more complex, actively managed strategy to select pharmaceutical stocks rather than simply tracking a broad market index.

What would affect this ETF?

PJP could benefit from ongoing demand for medicines, an aging U.S. population, and successful new drug launches by major holdings like AbbVie, Pfizer, Eli Lilly, and Johnson & Johnson, especially if health care policies remain supportive of innovation. On the negative side, tighter drug pricing rules, patent expirations, safety concerns, or slower economic growth in North America could hurt profits for these pharmaceutical companies and weigh on the ETF’s future returns.

PJP Top 10 Holdings

PJP is a pure play on big U.S. drugmakers, with heavy exposure to household pharma names. Amgen, Eli Lilly, and Gilead have been rising steadily, giving the fund much of its recent lift, while Pfizer and Johnson & Johnson add solid, if less exciting, support. On the flip side, Abbott has been lagging and acts as a bit of a speed bump, and Merck’s mixed near-term performance keeps it from fully pulling its weight. Overall, this is a concentrated bet on large-cap U.S. pharmaceuticals, with a few smaller players adding extra spice.

PJP top ten holdings
NameCompany NameWeight %Market ValueMarket CapYearly GainOverall Rating
LLYLLYEli Lilly & Co6.16%$37.42M$1.34T41.12%72Outperform
GILDGILDGilead Sciences6.03%$36.65M$208.31B34.25%78Outperform
ABBVABBVAbbVie5.87%$35.66M$520.47B27.01%66Neutral
AMGNAMGNAmgen5.59%$33.93M$252.64B38.59%77Outperform
PFEPFEPfizer5.45%$33.12M$164.33B12.02%74Outperform
JNJJNJJohnson & Johnson5.43%$32.98M$682.52B46.35%78Outperform
MRKMRKMerck & Company4.98%$30.23M$362.27B59.00%80Outperform
ABTABTAbbott Laboratories4.97%$30.19M$185.75B-16.05%73Outperform
VTRSVTRSViatris3.80%$23.07M$23.70B90.83%60Neutral
AMRXAMRXAmneal Pharmaceuticals3.65%$22.19M$7.56B85.59%58Neutral

PJP Technical Analysis

Technical Analysis SentimentPositive
Last Price131.04

Price Trends

50DMA125.82Positive
100DMA124.35Positive
200DMA115.29Positive

Market Momentum

MACD1.54Negative
RSI59.39Neutral
STOCH79.21Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PJP, the sentiment is Positive. The current price of 131.04 is above the 20-day moving average (MA) of 128.14, above the 50-day MA of 125.82, and above the 200-day MA of 115.29, indicating a bullish trend. The MACD of 1.54 indicates Negative momentum. The RSI at 59.39 is Neutral, neither overbought nor oversold. The STOCH value of 79.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PJP.

PJP Peer Comparison

Comparison Results

PJP against its peer funds
NamePricePrice TargetAUMExpense RatioOverall Rating
PJPPJP$131.04$137.00(4.55% Upside)$609.17M0.58%70Neutral
XPHXPH$66.83$111.69(67.13% Upside)$528.86M0.35%58Neutral
PBEPBE$97.88$127.77(30.53% Upside)$436.74M0.59%71Outperform
PINKPINK$39.98$50.79(27.03% Upside)$344.66M0.51%67Neutral
PTHPTH$57.32$78.62(37.17% Upside)$284.20M0.60%60Neutral
XHSXHS$145.43$171.66(18.04% Upside)$244.82M0.35%65Neutral

Performance Comparison

0%20%40%PJPXPHPBEPINKPTHXHSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
PJP and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
PJPInvesco Dynamic Pharmaceuticals ETF131.0429.0728.51%
XPHSPDR S&P Pharmaceuticals ETF66.8315.6830.67%
PBEInvesco Dynamic Biotechnology & Genome ETF97.8821.5428.21%
PINKSimplify Health Care ETF39.983.9611.00%
PTHInvesco DWA Healthcare Momentum ETF57.318.6117.68%
XHSSPDR S&P Health Care Services ETF145.4344.0243.41%
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.